866-997-4948(US-Canada Toll Free)

Natera Inc (NTRA) - Product Pipeline Analysis, 2018 Update

Published By :

GlobalData

Published Date : Aug 2018

Category :

Medical Equipments

No. of Pages : 46 Pages

Summary

Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers products such as panorama prenatal testing, pre-implantation genetic testing, miscarriage testing, genetic carrier screening and paternity testing. Its pre-implantation genetic testing includes translocation testing, aneuploidy screening, and single gene testing. Natera offers constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the companys algorithms and bioinformatics in order to validate and launch tests. The company also undertakes clinical trial of several genetic materials. Natera is headquartered in San Carlos, California, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Natera Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Natera Inc Company Overview 6
Natera Inc Company Snapshot 6
Natera Inc Pipeline Products and Ongoing Clinical Trials Overview 6
Natera Inc Pipeline Analysis Overview 9
Natera Inc - Key Facts 9
Natera Inc - Major Products and Services 10
Natera Inc Pipeline Products by Development Stage 11
Natera Inc Ongoing Clinical Trials by Trial Status 14
Natera Inc Pipeline Products Overview 16
Anora Natera Miscarriage POC Test 16
Anora Natera Miscarriage POC Test Product Overview 16
Constellation 17
Constellation Product Overview 17
dd-cfDNA Assay - Kidney Transplant Rejection 18
dd-cfDNA Assay - Kidney Transplant Rejection Product Overview 18
Horizon Carrier Screen Test 19
Horizon Carrier Screen Test Product Overview 19
Non-Invasive DNA Based Test - Breast Cancer 20
Non-Invasive DNA Based Test - Breast Cancer Product Overview 20
Non-Invasive DNA Based Test - Lung Cancer 21
Non-Invasive DNA Based Test - Lung Cancer Product Overview 21
Non-Invasive DNA Based Test - Ovarian Cancer 22
Non-Invasive DNA Based Test - Ovarian Cancer Product Overview 22
Non-invasive DNA Based Test - Therapeutic Monitoring 23
Non-invasive DNA Based Test - Therapeutic Monitoring Product Overview 23
Panorama Non-Invasive Prenatal Expanded Test 24
Panorama Non-Invasive Prenatal Expanded Test Product Overview 24
Panorama Non-Invasive Prenatal Expanded Test Clinical Trial 25
Signatera - Breast Cancer 27
Signatera - Breast Cancer Product Overview 27
Signatera - Colorectal Cancer 28
Signatera - Colorectal Cancer Product Overview 28
Spectrum PGD Test 29
Spectrum PGD Test Product Overview 29
Spectrum PGS Test 30
Spectrum PGS Test Product Overview 30
Vistara Non-Invasive Prenatal Test 31
Vistara Non-Invasive Prenatal Test Product Overview 31
Vistara Non-Invasive Prenatal Test Clinical Trial 32
Natera Inc - Key Competitors 33
Natera Inc - Key Employees 34
Natera Inc - Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Natera Inc, Recent Developments 36
Jun 21, 2018: Natera Develops Powerful Kidney Transplant Rejection Biomarker 36
Jun 19, 2018: Natera and Institut Jules Bordet partner on breast cancer research 36
Jun 13, 2018: Natera Announces New Clinical Utility Data and Issuance of CPT Code for NIPT in Twin Pregnancies 37
May 09, 2018: ECRI Institute Reveals Important Differences in Prenatal Genetic Tests 37
May 08, 2018: Natera Reports First Quarter 2018 Financial Results 38
Apr 13, 2018: Natera to Present Successful Results at AACR from Bladder and Colon Cancer Studies 39
Apr 09, 2018: Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer 39
Mar 13, 2018: Natera Announces Fourth Quarter And Fiscal Year 2017 Financial Results 40
Mar 05, 2018: Natera's Genetic Tests Now Fully Integrated into Yale New Haven Health's Epic EMR System 41
Jan 29, 2018: Natera To Feature Expanded Panorama Non-Invasive Prenatal Test, Now Validated for Twin Pregnancies, at SMFM Annual Meeting 42
Appendix 43
Methodology 43
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Natera Inc Pipeline Products and Ongoing Clinical Trials Overview 6
Natera Inc Pipeline Products by Equipment Type 7
Natera Inc Pipeline Products by Indication 8
Natera Inc Ongoing Clinical Trials by Trial Status 8
Natera Inc, Key Facts 9
Natera Inc, Major Products and Services 10
Natera Inc Number of Pipeline Products by Development Stage 11
Natera Inc Pipeline Products Summary by Development Stage 12
Natera Inc Ongoing Clinical Trials by Trial Status 14
Natera Inc Ongoing Clinical Trials Summary 15
Anora Natera Miscarriage POC Test - Product Status 16
Anora Natera Miscarriage POC Test - Product Description 16
Constellation - Product Status 17
Constellation - Product Description 17
dd-cfDNA Assay - Kidney Transplant Rejection - Product Status 18
dd-cfDNA Assay - Kidney Transplant Rejection - Product Description 18
Horizon Carrier Screen Test - Product Status 19
Horizon Carrier Screen Test - Product Description 19
Non-Invasive DNA Based Test - Breast Cancer - Product Status 20
Non-Invasive DNA Based Test - Breast Cancer - Product Description 20
Non-Invasive DNA Based Test - Lung Cancer - Product Status 21
Non-Invasive DNA Based Test - Lung Cancer - Product Description 21
Non-Invasive DNA Based Test - Ovarian Cancer - Product Status 22
Non-Invasive DNA Based Test - Ovarian Cancer - Product Description 22
Non-invasive DNA Based Test - Therapeutic Monitoring - Product Status 23
Non-invasive DNA Based Test - Therapeutic Monitoring - Product Description 23
Panorama Non-Invasive Prenatal Expanded Test - Product Status 24
Panorama Non-Invasive Prenatal Expanded Test - Product Description 24
Panorama Non-Invasive Prenatal Expanded Test - Development of Non-invasive Prenatal Diagnostic Test for Multiple Gestation Pregnancies Based on Fetal DNA Isolated from Maternal Blood 25
Panorama Non-Invasive Prenatal Expanded Test - Development of Non-invasive Prenatal Diagnostic Test for Multiple Gestation Pregnancies Based on Fetal DNA Isolated from Maternal Blood 25
Panorama Non-Invasive Prenatal Expanded Test - Development of Non-invasive Prenatal Test for Microdeletion/Duplication and Other Genetic Syndromes Based on Fetal DNA Isolated from Maternal Blood 25
Panorama Non-Invasive Prenatal Expanded Test - SNP-based Microdeletion and Aneuploidy Registry 26
Signatera - Breast Cancer - Product Status 27
Signatera - Breast Cancer - Product Description 27
Signatera - Colorectal Cancer - Product Status 28
Signatera - Colorectal Cancer - Product Description 28
Spectrum PGD Test - Product Status 29
Spectrum PGD Test - Product Description 29
Spectrum PGS Test - Product Status 30
Spectrum PGS Test - Product Description 30
Vistara Non-Invasive Prenatal Test - Product Status 31
Vistara Non-Invasive Prenatal Test - Product Description 31
Vistara Non-Invasive Prenatal Test - Development of Non-invasive Prenatal Diagnostic Test for Multiple Gestation Pregnancies Based on Fetal DNA Isolated from Maternal Blood 32
Natera Inc, Key Employees 34
Natera Inc, Subsidiaries 35
Glossary 45

List of Figures
Natera Inc Pipeline Products by Equipment Type 7
Natera Inc Pipeline Products by Development Stage 11
Natera Inc Ongoing Clinical Trials by Trial Status 14

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *